Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWiparat Manuyakornen_US
dc.contributor.authorKhanitha Siripoolen_US
dc.contributor.authorWasu Kamchaisatianen_US
dc.contributor.authorSamart Pakakasamaen_US
dc.contributor.authorAnannit Visudtibhanen_US
dc.contributor.authorSoamarat Vilaiyuken_US
dc.contributor.authorThidarat Rujirawaten_US
dc.contributor.authorSuwat Benjaponpitaken_US
dc.contributor.otherMahidol Universityen_US
dc.identifier.citationPediatric Allergy and Immunology. Vol.24, No.3 (2013), 299-303en_US
dc.description.abstractBackground: Aromatic anticonvulsant-induced severe cutaneous adverse drug reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrosis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are fatal immune-mediated adverse drug reactions. CYP2C19, a cytochrome P450 isoform, plays a role in metabolic rate of aromatic anticonvulsant. HLA-B*1502 has also been demonstrated to be associated with carbamazepine-induced SJS-TEN. Methods: Forty case patients who were diagnosed with SCARs after initiation of phenobarbital (PB), phenytoin (PHT), or carbamazepine (CBZ) for 1-8 wk and forty control patients who received PB, PHT, or CBZ at least 2 months with no adverse drug reactions were enrolled in the study. The genotypes of CYP2C19*1, CYP2C19*2, and HLA-B*1502 were analyzed using allele-specific polymerase chain reaction technique. Clinical characteristics of SCARs patients who used different drugs were also analyzed. Results: There was no significant difference in sex, onset of symptoms, laboratory results, treatment, and length of stay among patients with SCARs due to PB, PHT, or CBZ. The patients with CYP2C19*2 variant had a trend to have a likelihood to develop SCARs more than the patients with CYP2C19 wild type (OR = 2.5, 95% CI (0.96-67.3) p = 0.06). In subgroup analysis, the patients with CYP2C19*2 variant were at four times increased risk of SCARs from phenobarbital more than the patients with CYP2C19 wild type (OR = 4.5, 95% CI (1.17-17.37) p < 0.03). There was no association between the HLA-B*1502 and aromatic anticonvulsant-induced severe cutaneous adverse reactions (SCARs). Conclusion: CYP2C19*2 variant may play a role in the genetic predisposition of SCARs from phenobarbital. © 2013 John Wiley & Sons A/S.en_US
dc.rightsMahidol Universityen_US
dc.subjectImmunology and Microbiologyen_US
dc.titlePhenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai childrenen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.